Tuesday, 12 May 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 12 May 2026
News

Shake-up hits 2025 top-earners list

Posted 12 May 2026 AM

Eli Lilly is catching up to its market capitalisation, leaping up the rank of highest-earnings pharmaceutical companies after revenue grew 45 per cent in 2025.

In 2024 Lilly was the pharma with the tenth highest revenues, earning US$45 billion. In 2025 it was the third-highest earning pharma with US$65.2 billion in revenue, according to Fierce Pharma. It became the highest valued pharma three years ago, and last November was the first pharma to briefly pass a US$1 trillion market cap.

To see the whole article, please login

Popular

PBAC July Agenda blows out to 58
'Slow to respond' CSL nosedives
Novo's obesity pill hits the TGA
Patient advocate named Governor
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home